Nynomic AG and Kraemer Elektronik Unveil LabScanner Plus, Targeting Pharmaceutical Industry

Nynomic AG, in collaboration with Kraemer Elektronik, has launched the LabScanner Plus. This new technology combines Kraemer's casing and measuring capabilities with Nynomic’s advanced sensors to analyze pharmaceutical pills rapidly. Initially developed to detect counterfeit pharmaceuticals, the product is expected to interest quality assurance sectors within the industry.

The LabScanner Plus, following customer certification, is slated for initial sales within this fiscal year with an estimated revenue contribution of approximately €1 million. This project aligns with Nynomic's mid- to long-term strategic goals, potentially contributing a mid single-digit annual revenue increment over the next few years.

Despite last year's modest sales growth, Nynomic anticipates a 12% year-over-year growth rate in FY24, fueled by various factors, including sustained semi customer demand and new product launches like the LabScanner Plus. Nynomic also plans to expand through acquisitions with targets generating up to €20 million in sales. The company remains strategically poised for significant growth with an attractive share price based on a BUY rating and a €52 target price.